Samsung Biologics Secures 87.8% Stake in Polypeptide
Samsung Biologics has passed a decisive hurdle to acquire Polypeptide Group, a global peptide contract development and manufacturing organization (CDMO). As the preliminary results of the tender offer showed that the tendered stake significantly exceeded the minimum acceptance condition, the company
We haven't written up this one. BusinessKorea has the full story — the link below goes straight to it.